CD274 and cancer: Cancer patients treated with PD(L)-1 blockade during the pre-infectious phase of SARS-CoV-2 are more resistant to the attack from the virus (142), and during the early phase of SARS-CoV-2 infection such therapy can contribute to the viral clearance (141).